Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/53274 |
Resumo: | © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
id |
RCAP_53acb42a81ac2e0a7595229a8a101ad9 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/53274 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)ColchicineCost effectivenessMyocardial infarction© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comAims: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina leading to coronary revascularization. To assess the in-trial period and lifetime cost-effectiveness of low-dose colchicine therapy compared to placebo in post-MI patients on standard-of-care therapy. Methods and results: A multistate Markov model was developed incorporating the primary efficacy and safety results from COLCOT, as well as healthcare costs and utilities from the Canadian healthcare system perspective. All components of the primary outcome, non-cardiovascular deaths, and pneumonia were included as health states in the model as both primary and recurrent events. In the main analysis, a deterministic approach was used to estimate the incremental cost-effectiveness ratio (ICER) for the trial period (24 months) and lifetime (20 years). Over the in-trial period, the addition of colchicine to post-MI standard-of-care treatment decreased the mean overall per-patient costs by 47%, from $502 to $265 Canadian dollar (CAD), and increased the quality-adjusted life years (QALYs) from 1.30 to 1.34. The lifetime per-patient costs were further reduced (69%) and QALYs increased with colchicine therapy (from 8.82 to 11.68). As a result, both in-trial and lifetime ICERs indicated colchicine therapy was a dominant strategy. Conclusion: Cost-effectiveness analyses indicate that the addition of colchicine to standard-of-care therapy after MI is economically dominant and therefore generates cost savings.Oxford University PressRepositório da Universidade de LisboaSamuel, MichelleTardif, Jean-ClaudeKhairy, PaulRoubille, FrançoisWaters, David DGrégoire, Jean CPinto, Fausto J.Maggioni, Aldo P.Diaz, RafaelBerry, ColinKoenig, WolfgangOstadal, PetrLopez-Sendon, JoseGamra, HabibKiwan, Ghassan S.Dubé, Marie-PierreProvencher, MylèneOrfanos, AndreasBlondeau, LucieKouz, SimonL’Allier, Philippe L.Ibrahim, RedaBouabdallaoui, NadiaMitchell, DominicGuertin, Marie-ClaudeLelorier, Jacques2022-06-06T13:17:42Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/53274engEur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-4952058-522510.1093/ehjqcco/qcaa0452058-1742info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-11-20T18:14:46Zoai:repositorio.ul.pt:10451/53274Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-20T18:14:46Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
title |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
spellingShingle |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) Samuel, Michelle Colchicine Cost effectiveness Myocardial infarction |
title_short |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
title_full |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
title_fullStr |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
title_full_unstemmed |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
title_sort |
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
author |
Samuel, Michelle |
author_facet |
Samuel, Michelle Tardif, Jean-Claude Khairy, Paul Roubille, François Waters, David D Grégoire, Jean C Pinto, Fausto J. Maggioni, Aldo P. Diaz, Rafael Berry, Colin Koenig, Wolfgang Ostadal, Petr Lopez-Sendon, Jose Gamra, Habib Kiwan, Ghassan S. Dubé, Marie-Pierre Provencher, Mylène Orfanos, Andreas Blondeau, Lucie Kouz, Simon L’Allier, Philippe L. Ibrahim, Reda Bouabdallaoui, Nadia Mitchell, Dominic Guertin, Marie-Claude Lelorier, Jacques |
author_role |
author |
author2 |
Tardif, Jean-Claude Khairy, Paul Roubille, François Waters, David D Grégoire, Jean C Pinto, Fausto J. Maggioni, Aldo P. Diaz, Rafael Berry, Colin Koenig, Wolfgang Ostadal, Petr Lopez-Sendon, Jose Gamra, Habib Kiwan, Ghassan S. Dubé, Marie-Pierre Provencher, Mylène Orfanos, Andreas Blondeau, Lucie Kouz, Simon L’Allier, Philippe L. Ibrahim, Reda Bouabdallaoui, Nadia Mitchell, Dominic Guertin, Marie-Claude Lelorier, Jacques |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Samuel, Michelle Tardif, Jean-Claude Khairy, Paul Roubille, François Waters, David D Grégoire, Jean C Pinto, Fausto J. Maggioni, Aldo P. Diaz, Rafael Berry, Colin Koenig, Wolfgang Ostadal, Petr Lopez-Sendon, Jose Gamra, Habib Kiwan, Ghassan S. Dubé, Marie-Pierre Provencher, Mylène Orfanos, Andreas Blondeau, Lucie Kouz, Simon L’Allier, Philippe L. Ibrahim, Reda Bouabdallaoui, Nadia Mitchell, Dominic Guertin, Marie-Claude Lelorier, Jacques |
dc.subject.por.fl_str_mv |
Colchicine Cost effectiveness Myocardial infarction |
topic |
Colchicine Cost effectiveness Myocardial infarction |
description |
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 2021-01-01T00:00:00Z 2022-06-06T13:17:42Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/53274 |
url |
http://hdl.handle.net/10451/53274 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-495 2058-5225 10.1093/ehjqcco/qcaa045 2058-1742 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Oxford University Press |
publisher.none.fl_str_mv |
Oxford University Press |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817549190845169664 |